<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867957</url>
  </required_header>
  <id_info>
    <org_study_id>GC1109_P1_v1.2</org_study_id>
    <nct_id>NCT01867957</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Anthrax Vaccine, GC1109</brief_title>
  <official_title>A Single Blind, Randomized, Placebo Control, Phase I Study to Evaluate the Safety and Immunogenicity of the GC1109 Administered by the Intramuscular Route in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LSK Global Pharma Services Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      1. BACKGROUND The newly developed anthrax vaccine GC1109 has been proven safe and effective
           in preclinical studies.

        2. OBJECTIVE

           - To evaluate the immunogenicity and safety of the anthrax vaccine GC1109 in healthy
           male volunteers.

        3. STUDY DESIGN

             -  single-blinded

             -  randomized

             -  placebo controlled

             -  phase 1 study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>0 - 28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-protective antigen(PA) antibody level (by TNA)</measure>
    <time_frame>Day 14, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PA Immunoglobulin G (IgG) (by ELISA)</measure>
    <time_frame>Day 14, Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Anthrax</condition>
  <arm_group>
    <arm_group_label>Low-dose GC1109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose GC1109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-dose GC1109</intervention_name>
    <description>50ug/dose</description>
    <arm_group_label>Low-dose GC1109</arm_group_label>
    <other_name>GC1109 50ug/dose (0.5 ml) vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose GC1109</intervention_name>
    <description>100ug/dose</description>
    <arm_group_label>High-dose GC1109</arm_group_label>
    <other_name>GC1109 100ug/dose (1.0 ml) vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-dose Placebo</intervention_name>
    <description>0.9% Saline 0.5 mL</description>
    <arm_group_label>Low-dose Placebo</arm_group_label>
    <other_name>0.9% Saline 0.5 mL vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dose Placebo</intervention_name>
    <description>0.9% Saline 1.0 mL</description>
    <arm_group_label>High-dose Placebo</arm_group_label>
    <other_name>0.9% Saline 1.0 mL vaccination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects between 18 and 45 years of age at the time of screening visit

          2. 18.5kg/m2 â‰¤BMI &lt; 30kg/m2 at the time of screening visit

          3. Subjects without congenital or chronic disorder

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoung-don Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Myoung-don Oh</investigator_full_name>
    <investigator_title>Professor, Division of Infectious Diseases, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>anthrax</keyword>
  <keyword>vaccine</keyword>
  <keyword>bioterrorism</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

